Abstract

BackgroundThis study aims to evaluate the role of the fibrinogen/albumin ratio (FAR) in predicting platinum resistance and survival outcomes of patients with ovarian clear cell carcinoma (OCCC).MethodsCoagulation function and D-dimer, serum albumin, CA125 and HE4 levels were measured before surgery in OCCC patients undergoing initial surgery in our institution. FAR was calculated as fibrinogen/albumin level. The correlation between these indicators and clinicopathological features, platinum response, and survival outcomes was further analyzed. The Kaplan-Meier method and multivariable Cox regression model were used to assess the effects of FAR on progression-free survival (PFS) and overall survival (OS).ResultsAdvanced stage patients accounted for 42.1% of the 114 participants. Optimal cytoreductive surgery was achieved in 105 patients, and the complete resection rate was 78.1%. FAR was associated with tumor stage, residual tumor and platinum response. A receiver operating characteristic curve for predicting platinum response showed that the optimal cutoff point of the FAR was 12%. The sensitivity was 73.3% and the specificity was 68.2%. In multivariate analysis, FAR ≥12% (HR = 4.963, P = 0.002) was an independent risk factor for platinum resistance. In addition, FAR and D-dimer proved to be independent negative factors for outcomes including both PFS and OS. The median follow-up time was 52 months. A high FAR (≥ 12%) showed a stronger correlation with poor OS and PFS in the subgroup analysis of advanced and completely resected patients.ConclusionsThe FAR might be a potential preoperative biochemical marker for predicting treatment response and oncological outcomes in OCCC patients.

Highlights

  • This study aims to evaluate the role of the fibrinogen/albumin ratio (FAR) in predicting platinum resistance and survival outcomes of patients with ovarian clear cell carcinoma (OCCC)

  • A FAR ≥12% was an independent negative factor for both progression-free survival (PFS) (HR = 2.228, P = 0.009) and overall survival (OS) (HR = 3.606, P < 0.001), as well as high D-dimer, advanced stage and residual tumor

  • OCCC is known to be less sensitive to platinum-based front-line chemotherapy and have an overall poor prognosis compared to other types of epithelial ovarian cancers, especially in advanced stages [6]

Read more

Summary

Introduction

This study aims to evaluate the role of the fibrinogen/albumin ratio (FAR) in predicting platinum resistance and survival outcomes of patients with ovarian clear cell carcinoma (OCCC). Fibrinogen, one of the important indicators of the coagulation function, is an acute-phase protein, and its plasma level increases during the systemic inflammatory response [9]. It has attracted increasing attention because of its important role in the development and progression of inflammation and cancer [10,11,12]. Few studies have explored the value of the FAR in OCCC

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call